PMID- 29352658
OWN - NLM
STAT- MEDLINE
DCOM- 20180404
LR  - 20180404
IS  - 1347-8648 (Electronic)
IS  - 1347-8613 (Linking)
VI  - 136
IP  - 1
DP  - 2018 Jan
TI  - Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse 
      obstructed kidney: Special references to HIF-1 dependent gene expression of 
      profibrogenic molecules.
PG  - 31-38
LID - S1347-8613(17)30207-4 [pii]
LID - 10.1016/j.jphs.2017.12.004 [doi]
AB  - The aim of the study is to clarify the role of hypoxia-inducible factor-1 (HIF-1) 
      in the development of renal fibrosis in mouse obstructive nephropathy. We used 
      mice with floxed HIF-1alpha alleles and tamoxifen-inducible Cre/ERT2 recombinase 
      under ubiquitin C promoter to induce global HIF-1alpha deletion. Following tamoxifen 
      administration, mice were subjected to unilateral ureteral obstruction (UUO). At 
      3, 7 and 14 days after UUO, renal gene expression profiles and interstitial 
      fibrosis were assessed. HIF-1 dependent up-regulation of prolyl hydroxylase 3 and 
      glucose transporter-1 was observed in the obstructed kidney at 3 and 7 days but 
      not at 14 days after UUO. Various factors promoting fibrosis were up-regulated 
      during the development of fibrosis. HIF-1 dependent gene expression of 
      profibrotic molecules, plasminogen activator inhibitor 1, connective tissue 
      growth factor, lysyl oxidase like 2 and transglutaminase 2 was observed in the 
      obstructed kidney but such HIF-1 dependency was limited to the early onset of 
      renal fibrosis. Global HIF-1 deletion tended to attenuate interstitial collagen I 
      deposition at 3 days but had no effects thereafter. It is suggested that HIF-1 
      dependent profibrogenic mechanisms are operating at the early onset of renal 
      fibrosis but its contribution declines with the progression in mouse UUO model.
CI  - Copyright (c) 2018 The Authors. Production and hosting by Elsevier B.V. All rights 
      reserved.
FAU - Kabei, Kazuya
AU  - Kabei K
AD  - Department of Applied Pharmacology and Therapeutics, Osaka City University 
      Graduate School of Medicine, Asahimachi, Abeno-ku, Osaka 545-8585, Japan; 
      Department of Urology, Osaka City University Graduate School of Medicine, 
      Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
FAU - Tateishi, Yu
AU  - Tateishi Y
AD  - Ishikiri Seiki Hospital, Yayoi-cho, Higashiosaka, Osaka 579-8026, Japan.
FAU - Nozaki, Masakazu
AU  - Nozaki M
AD  - Department of Applied Pharmacology and Therapeutics, Osaka City University 
      Graduate School of Medicine, Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
FAU - Tanaka, Masako
AU  - Tanaka M
AD  - Department of Applied Pharmacology and Therapeutics, Osaka City University 
      Graduate School of Medicine, Asahimachi, Abeno-ku, Osaka 545-8585, Japan; 
      Department of Life Science and Medical BioScience, School of Advanced Science and 
      Engineering, Waseda University, Wakamatsu-cho, Shinjuku-ku, Tokyo, 162-8480, 
      Japan.
FAU - Shiota, Masayuki
AU  - Shiota M
AD  - Department of Research Support Platform, Osaka City University Graduate School of 
      Medicine, Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
FAU - Osada-Oka, Mayuko
AU  - Osada-Oka M
AD  - Food Hygiene and Environmental Health, Division of Applied Life Science, Graduate 
      School of Life and Environmental Sciences, Kyoto Prefectural University, 
      Sakyo-ku, Kyoto 606-8522, Japan.
FAU - Nishide, Shunji
AU  - Nishide S
AD  - Department of Urology, Osaka City University Graduate School of Medicine, 
      Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
FAU - Uchida, Junji
AU  - Uchida J
AD  - Department of Urology, Osaka City University Graduate School of Medicine, 
      Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
FAU - Nakatani, Tatsuya
AU  - Nakatani T
AD  - Department of Urology, Osaka City University Graduate School of Medicine, 
      Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
FAU - Tomita, Shuhei
AU  - Tomita S
AD  - Department of Pharmacology, Osaka City University Graduate School of Medicine, 
      Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
FAU - Miura, Katsuyuki
AU  - Miura K
AD  - Department of Applied Pharmacology and Therapeutics, Osaka City University 
      Graduate School of Medicine, Asahimachi, Abeno-ku, Osaka 545-8585, Japan. 
      Electronic address: miura-pha@med.osaka-cu.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20171228
PL  - Japan
TA  - J Pharmacol Sci
JT  - Journal of pharmacological sciences
JID - 101167001
RN  - 0 (Glucose Transporter Type 1)
RN  - 0 (Hif1a protein, mouse)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 139568-91-5 (Connective Tissue Growth Factor)
RN  - 9007-34-5 (Collagen)
RN  - EC 1.14.11.- (Prolyl Hydroxylases)
SB  - IM
MH  - Animals
MH  - Collagen/genetics
MH  - Connective Tissue Growth Factor/genetics/metabolism
MH  - Disease Models, Animal
MH  - Fibrosis
MH  - Gene Expression/*genetics
MH  - Glucose Transporter Type 1/genetics/metabolism
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*physiology
MH  - Kidney/*pathology
MH  - Plasminogen Activator Inhibitor 1/genetics/metabolism
MH  - Prolyl Hydroxylases/genetics/metabolism
MH  - Up-Regulation/genetics
MH  - Ureteral Obstruction/*genetics/*pathology
OTO - NOTNLM
OT  - HIF-1alpha
OT  - Hypoxia
OT  - Hypoxia-inducible factor
OT  - Renal fibrosis
EDAT- 2018/01/21 06:00
MHDA- 2018/04/05 06:00
CRDT- 2018/01/21 06:00
PHST- 2017/10/25 00:00 [received]
PHST- 2017/11/28 00:00 [revised]
PHST- 2017/12/05 00:00 [accepted]
PHST- 2018/01/21 06:00 [pubmed]
PHST- 2018/04/05 06:00 [medline]
PHST- 2018/01/21 06:00 [entrez]
AID - S1347-8613(17)30207-4 [pii]
AID - 10.1016/j.jphs.2017.12.004 [doi]
PST - ppublish
SO  - J Pharmacol Sci. 2018 Jan;136(1):31-38. doi: 10.1016/j.jphs.2017.12.004. Epub 
      2017 Dec 28.